A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Volumn 33, Issue 9, 2018, Pages 1628-1635

  Huang, Louis L ^a,b   Lee, Darren ^a,b   Troster, Stefanie M ^a   Kent, Annette B ^a   Roberts, Matthew A ^a,b   Macdougall, Iain C ^c   McMahon, Lawrence P ^a,b  

^a EASTERN HEALTH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; BIOLOGICAL MARKER; FERRIC CARBOXYMALTOSE; FERRIC ION; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; MALTOSE; PHOSPHATE;

AUSTRALIA; BLOOD; BONE; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPOPHOSPHATASIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; PREGNANCY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; AUSTRALIA; BIOMARKERS; BONE AND BONES; CASE-CONTROL STUDIES; FEMALE; FERRIC COMPOUNDS; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HEMATINICS; HUMANS; HYPOPHOSPHATASIA; MALE; MALTOSE; MIDDLE AGED; PHOSPHATES; PREGNANCY; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 85061480417     PISSN: None     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfx310     Document Type: Article

References (0)